Cysview: Who It’s For
Anyone who is suspected of having or is known to have bladder cancer (from a previous cystoscopy) can have BLC with Cysview.
Ideally, it should be used in:
- first transurethral resection of bladder tumor (TURBT)
- first follow-up cystoscopy
- the management of intermediate-risk patients
- the management of high-risk patients
For use in first TURBT and the management of intermediate and high-risk patients1
Recommended patient types2,3
- Patients receiving first TURBT because of suspicion of non-muscle invasive bladder cancer (NMIBC)
- Patients receiving repeat TURBT
- Patients who received BCG treatment (to assess response after 6 weeks)
- Patients undergoing surveillance
- Referred patients (who have not previously had a Blue Light Cystoscopy with Cysview) who will be receiving intravesical therapy when residual disease is suspected
- Patients with positive cytology and negative White Light Cystoscopy
Cysview may not detect all bladder tumors and is not a replacement for random biopsies.
1 Cysview [prescribing Information]. 2018:1-14.
2 Daneshmand S, Schuckman AK, Bochner BH, et al. Hexaminolevulinate Blue-Light Cystoscopy in Non-Muscle-Invasive Bladder Cancer: Review of the Clinical Evidence and Consensus Statement on Appropriate Use in the USA. Nat Rev Urol. 2014;11(10):589-596.
3 Lotan Y, Bivalacqua TJ, Downs T, et. al. Blue Light Flexible Cystoscopy with Hexaminolevulinate in Non-Muscle Invasive Bladder Cancer: Review of the Clinical Evidence and Consensus Statement on Optimal Use in the USA — Update 2018. Nat Rev Urol. 2019;16(6):377-386.